Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534143 | 0.91 | PPARG (0.67) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL9995227 | 0.85 | PPARG (0.66) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL9995234 | 0.85 | PPARG (0.66) | PPARGPPARAMEN1GMNNEGFR | |
| Diethylamine SCHEMBL7923218 | 0.83 | PPARG (0.61) | PPARGPPARAMEN1GMNNEGFR | |
| Diethylamine SCHEMBL7976751 | 0.83 | PPARG (0.61) | PPARGPPARAMEN1GMNNEGFR | |
| Diethylamine SCHEMBL7920745 | 0.83 | PPARG (0.61) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL3534804 | 0.78 | PPARG (0.56) | PPARGPPARA | |
| SCHEMBL3542196 | 0.78 | PPARG (0.56) | PPARGPPARA | |
| SCHEMBL7974496 | 0.78 | PPARG (0.56) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL6254949 | 0.78 | PPARG (0.65) | PPARGPPARAMEN1GMNNEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578716-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2005-09-28 | — | — | EP | claimed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | claimed |
| WO-2004056740-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | claimed |
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1578716-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | disclosed |
| WO-2004056740-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259950-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885ITGB1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.